8-K: Carisma Therapeutics Announces Promising Early Results in HER2+ Cancer Trial

Carisma Therapeutics reports that 75% of HER2 3+ cancer patients in a Phase 1 trial experienced a reduction in circulating tumor DNA (ctDNA) after treatment with CT-0508.

Summary

• Carisma Therapeutics has released new analysis from its Phase 1 clinical trial of CT-0508, a therapy targeting HER2 overexpressing cancers.
• The analysis focused on circulating tumor DNA (ctDNA) levels in 13 patients from groups 1 and 2 of the trial.
• 75% of evaluable HER2 3+ patients (6 out of 8) showed a reduction in ctDNA, indicating direct tumor killing activity.
• The median decrease in ctDNA for these patients was 81%, with a range from 33% to 93% four weeks post-treatment.
• No ctDNA reduction was observed in the 5 evaluable HER2 2+ patients.
• The company believes these results support the potential for repeat dosing with their follow-on product, CT-0525.
• Enrollment in the CT-0508 trial and its sub-study with pembrolizumab was halted in April 2024 as part of a revised operating plan.
• All activities related to enrolled patients in the Phase 1 trial and sub-study have been completed as of July 2024.
• The company expects to provide further clinical data updates in the third quarter of 2024.

Sentiment

Score: 7

Explanation: The document presents promising early results for HER2 3+ patients, but also notes the halt of the trial and the lack of response in HER2 2+ patients. The overall sentiment is cautiously optimistic.

Positives

• The observed ctDNA reduction in HER2 3+ patients suggests that CT-0508 has direct tumor killing activity.
• The significant median decrease of 81% in ctDNA levels is a promising indicator of efficacy.
• The results support the potential for repeat dosing with CT-0525 to prolong pharmacologic efficacy and response.
• The company has completed all activities for patients enrolled in the Phase 1 clinical trial and sub-study.

Negatives

• No ctDNA reduction was observed in HER2 2+ patients, suggesting the therapy may not be effective for this subgroup.
• Enrollment in the CT-0508 trial and its sub-study was halted in April 2024.
• The results are preliminary and from a limited number of patients.

Risks

• The results are based on a small sample size and are preliminary.
• The trial was halted in April 2024, which may impact the overall development timeline.
• The therapy may not be effective for all HER2 overexpressing cancers, as indicated by the lack of response in HER2 2+ patients.
• The company is relying on future data from CT-0525 to demonstrate improved efficacy.

Future Outlook

The company believes that repeat dosing of its follow-on product, CT-0525, in patients with HER2 overexpressing cancers could prolong pharmacologic efficacy and response. The company expects clinical data updates in the third quarter of 2024.

Management Comments

• The company believes that repeat dosing of its follow-on product, CT-0525, in patients with HER2 overexpressing cancers could prolong pharmacologic efficacy and response.

Industry Context

The development of CAR-T and CAR-macrophage therapies is a growing area in oncology, with many companies exploring different targets and approaches. Carisma's focus on HER2 and the use of macrophages is part of this broader trend.

Comparison to Industry Standards

• The 75% ctDNA reduction in HER2 3+ patients is a promising result compared to other early-stage trials in similar therapies.
• Companies like Kite Pharma and Novartis have shown success with CAR-T therapies, but Carisma's approach using macrophages is a novel approach.
• The median decrease of 81% in ctDNA is a strong signal, but further data is needed to compare it to established benchmarks.
• The lack of response in HER2 2+ patients highlights the need for further research and potentially different treatment strategies for this subgroup.

Stakeholder Impact

• Shareholders may react positively to the promising early results in HER2 3+ patients.
• Patients with HER2 3+ cancers may have a new potential treatment option.
• Employees may be impacted by the revised operating plan and the halt of the CT-0508 trial.

Next Steps

• The company will continue to analyze the data from the Phase 1 clinical trial.
• The company will focus on the development of CT-0525.
• The company expects to provide clinical data updates in the third quarter of 2024.

Key Dates

Keywords

HER2, ctDNA, cancer, clinical trial, CT-0508, CT-0525, macrophage, immunotherapy, oncology